{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:24:12Z","timestamp":1790958252488,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.atherosclerosis.2008.05.021","type":"journal-article","created":{"date-parts":[[2008,5,22]],"date-time":"2008-05-22T08:53:12Z","timestamp":1211446392000},"page":"18-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Molecular basis of statin-associated myopathy"],"prefix":"10.1016","volume":"202","author":[{"given":"Christos","family":"Vaklavas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiannis S.","family":"Chatzizisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Ziakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysanthos","family":"Zamboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Giannoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5519","key":"10.1016\/j.atherosclerosis.2008.05.021_bib1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"issue":"6257","key":"10.1016\/j.atherosclerosis.2008.05.021_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2008.05.021_bib3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2008.05.021_bib4","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2008.05.021_bib5","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.str.0000034125.94759.41","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"33","author":"Pasternak","year":"2002","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2008.05.021_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejim.2006.09.020","article-title":"The syndrome of rhabdomyolysis: pathophysiology and diagnosis","volume":"18","author":"Giannoglou","year":"2007","journal-title":"Eur J Int Med"},{"issue":"8A","key":"10.1016\/j.atherosclerosis.2008.05.021_bib7","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2008.05.021_bib8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","article-title":"Current overview of statin-induced myopathy","volume":"116","author":"Rosenson","year":"2004","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2008.05.021_bib9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2008.05.021_bib10","first-page":"640","article-title":"Statin-induced myositis: a commonly encountered or rare side effect?","volume":"16","author":"Mukhtar","year":"2005","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2008.05.021_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1074248406288758","article-title":"Statin-induced myopathy: the two faces of Janus","volume":"11","author":"Arora","year":"2006","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2008.05.021_bib12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.amjmed.2006.02.007","article-title":"Clinical perspectives of statin-induced rhabdomyolysis","volume":"119","author":"Antons","year":"2006","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2008.05.021_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0165-6147(97)01147-4","article-title":"Hydrophilicity\/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors","volume":"19","author":"Hamelin","year":"1998","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2008.05.021_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/taap.1998.8491","article-title":"Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study","volume":"152","author":"Nakahara","year":"1998","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2008.05.021_bib15","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1203\/00006450-199606000-00016","article-title":"Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats","volume":"39","author":"Reijneveld","year":"1996","journal-title":"Pediatr Res"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2008.05.021_bib16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/taap.1995.1058","article-title":"In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes","volume":"131","author":"Masters","year":"1995","journal-title":"Toxicol Appl Pharmacol"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2008.05.021_bib17","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0022-2828(95)92163-X","article-title":"Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin","volume":"27","author":"Gadbut","year":"1995","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2008.05.021_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2008.05.021_bib19","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2008.05.021_bib20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/dmd.30.5.505","article-title":"Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2008.05.021_bib21","first-page":"23","article-title":"Drug-induced myopathies. An overview of the possible mechanisms","volume":"57","author":"Owczarek","year":"2005","journal-title":"Pharmacol Rep"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2008.05.021_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00018-005-5298-6","article-title":"Isoprenylated proteins","volume":"63","author":"McTaggart","year":"2006","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2008.05.021_bib23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nri1839","article-title":"Statin therapy and autoimmune disease: from protein prenylation to immunomodulation","volume":"6","author":"Greenwood","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"32","key":"10.1016\/j.atherosclerosis.2008.05.021_bib24","doi-asserted-by":"crossref","first-page":"11821","DOI":"10.1073\/pnas.0601617103","article-title":"Rabs and their effectors: achieving specificity in membrane traffic","volume":"103","author":"Grosshans","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2008.05.021_bib25","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1091\/mbc.e02-11-0707","article-title":"Dual prenylation is required for Rab protein localization and function","volume":"14","author":"Calero","year":"2003","journal-title":"Mol Biol Cell"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2008.05.021_bib26","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1091\/mbc.e02-10-0639","article-title":"Membrane targeting of Rab GTPases is influenced by the prenylation motif","volume":"14","author":"Gomes","year":"2003","journal-title":"Mol Biol Cell"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2008.05.021_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mus.10302","article-title":"Nuclear envelope proteins and neuromuscular diseases","volume":"27","author":"Ostlund","year":"2003","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2008.05.021_bib28","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/MCB.21.11.3840-3852.2001","article-title":"Selective inhibition of selenocysteine tRNA maturation and selenoprotein synthesis in transgenic mice expressing isopentenyladenosine-deficient selenocysteine tRNA","volume":"21","author":"Moustafa","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"36","key":"10.1016\/j.atherosclerosis.2008.05.021_bib29","doi-asserted-by":"crossref","first-page":"28110","DOI":"10.1074\/jbc.M001280200","article-title":"Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine","volume":"275","author":"Warner","year":"2000","journal-title":"J Biol Chem"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2008.05.021_bib30","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0024-3205(99)00199-X","article-title":"Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors","volume":"65","author":"Moghadasian","year":"1999","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2008.05.021_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/taap.1997.8131","article-title":"Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol Appl Pharmacol"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2008.05.021_bib32","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.bcp.2003.08.011","article-title":"Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes","volume":"66","author":"Nishimoto","year":"2003","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2008.05.021_bib33","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0022-2275(20)37182-0","article-title":"Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts","volume":"38","author":"Matzno","year":"1997","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2008.05.021_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5551\/jat.12.121","article-title":"Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins","volume":"12","author":"Morikawa","year":"2005","journal-title":"J Atheroscler Thromb"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2008.05.021_bib35","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1211\/jpp.57.11.0014","article-title":"Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein","volume":"57","author":"Matzno","year":"2005","journal-title":"J Pharm Pharmacol"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2008.05.021_bib36","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1096\/fj.07-8713com","article-title":"Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers","volume":"21","author":"Sakamoto","year":"2007","journal-title":"FASEB J"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2008.05.021_bib37","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1083\/jcb.110.5.1489","article-title":"Isoprenylation is required for the processing of the lamin A precursor","volume":"110","author":"Beck","year":"1990","journal-title":"J Cell Biol"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2008.05.021_bib38","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1073\/pnas.89.7.3000","article-title":"Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina","volume":"89","author":"Lutz","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"32","key":"10.1016\/j.atherosclerosis.2008.05.021_bib39","doi-asserted-by":"crossref","first-page":"19937","DOI":"10.1016\/S0021-9258(17)45464-0","article-title":"Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis","volume":"265","author":"Sinensky","year":"1990","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2008.05.021_bib40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1172\/JCI200419670","article-title":"Lamin A\/C deficiency causes defective nuclear mechanics and mechanotransduction","volume":"113","author":"Lammerding","year":"2004","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2008.05.021_bib41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1172\/JCI200419448","article-title":"Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A\/C-deficient mice","volume":"113","author":"Nikolova","year":"2004","journal-title":"J Clin Invest"},{"issue":"37","key":"10.1016\/j.atherosclerosis.2008.05.021_bib42","doi-asserted-by":"crossref","first-page":"38353","DOI":"10.1074\/jbc.M404838200","article-title":"Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways","volume":"279","author":"Siddals","year":"2004","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2008.05.021_bib43","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/mus.20291","article-title":"Molecular clues into the pathogenesis of statin-mediated muscle toxicity","volume":"31","author":"Baker","year":"2005","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2008.05.021_bib44","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0165-6147(03)00050-6","article-title":"Protein glycosylation in disease: new insights into the congenital muscular dystrophies","volume":"24","author":"Martin-Rendon","year":"2003","journal-title":"Trends Pharmacol Sci"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2008.05.021_bib45","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2008.05.021_bib46","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.amjcard.2007.12.005","article-title":"Coenzyme q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy?","volume":"101","author":"Chatzizisis","year":"2008","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2008.05.021_bib47","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme q10 on myopathic symptoms in patients treated with statins","volume":"99","author":"Caso","year":"2007","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2008.05.021_bib48","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","article-title":"Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia","volume":"100","author":"Young","year":"2007","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2008.05.021_bib49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"Paiva","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"8A","key":"10.1016\/j.atherosclerosis.2008.05.021_bib50","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"issue":"9601","key":"10.1016\/j.atherosclerosis.2008.05.021_bib51","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2008.05.021_bib52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-200767010-00002","article-title":"Squalene synthase inhibitors: clinical pharmacology and cholesterol-lowering potential","volume":"67","author":"Charlton-Menys","year":"2007","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2008.05.021_bib53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1742-1241.2005.00461.x","article-title":"Pitavastatin","volume":"59","author":"Mukhtar","year":"2005","journal-title":"Int J Clin Pract"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915008003560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915008003560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:29:49Z","timestamp":1758155389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915008003560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0021915008003560"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.05.021","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular basis of statin-associated myopathy","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}